Immunotherapy with Tolerogenic Dendritic Cells Alone or in Combination with Rapamycin Does Not Reverse Diabetes in NOD Mice
Pujol Autonell, Irma (Institut Germans Trias i Pujol. Banc de Sang i Teixits)
Ampudia, Rosa Maria (Institut Germans Trias i Pujol. Banc de Sang i Teixits)
Monge, Pau (Institut Germans Trias i Pujol. Banc de Sang i Teixits)
Lucas, Anna M. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Carrascal, Jorge (Immunology Unit, Department of Ciencies Basiques Mediques, Faculty of Medicine, University of Lleida & IRBLleida, 25198 Lleida, Spain)
Verdaguer, Joan (Immunology Unit, Department of Ciencies Basiques Mediques, Faculty of Medicine, University of Lleida & IRBLleida, 25198 Lleida, Spain)
Vives Pi, Marta (Institut Germans Trias i Pujol. Banc de Sang i Teixits)

Date:	2013
Abstract:	Type 1 diabetes is a metabolic disease caused by autoimmunity towards β -cells. Different strategies have been developed to restore β -cell function and to reestablish immune tolerance to prevent and cure the disease. Currently, there is no effective treatment strategy to restore endogenous insulin secretion in patients with type 1 diabetes. This study aims to restore insulin secretion in diabetic mice with experimental antigen-specific immunotherapy alone or in combination with rapamycin, a compound well known for its immunomodulatory effect. Nonobese diabetic (NOD) mice develop spontaneous type 1 diabetes after 12 weeks of age. Autologous tolerogenic dendritic cells—consisting in dendritic cells pulsed with islet apoptotic cells—were administered to diabetic NOD mice alone or in combination with rapamycin. The ability of this therapy to revert type 1 diabetes was determined by assessing the insulitis score and by measuring both blood glucose levels and C-peptide concentration. Our findings indicate that tolerogenic dendritic cells alone or in combination with rapamycin do not ameliorate diabetes in NOD mice. These results suggest that alternative strategies may be considered for the cure of type 1 diabetes.
Note:	Ajudes rebudes: Departament de Salut de la Generalitat de Catalunya; AGAUR
Note:	Número d'acord de subvenció FIS/PS09/0025
Note:	Número d'acord de subvenció FIS/PI12/0019
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès.
Document:	article ; recerca ; publishedVersion
Subject:	Immunoteràpia
Published in:	ISRN Endocrinology, Vol. 2013 (march 2013) , ISSN 2090-4649

PMID: 23555060

5 p, 584.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles